Experimental Four-Target antibody tested for tough brain cancers
NCT ID NCT05485753
Summary
This early-stage study is testing a new, four-target antibody drug called GNC-038 in adults with primary or secondary brain lymphoma that has come back or hasn't responded to other treatments. The main goals are to find a safe dose, understand how the body processes the drug, and see if it shows any early signs of fighting the cancer. It is for patients who have few other treatment options left.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing GoBroad Boren Hospital
Beijing, Beijing Municipality, China
-
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, 100070, China
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Conditions
Explore the condition pages connected to this study.